The announcement of the FDA’s decision to delay the active enforcement date for the Drug Supply Chain Security Act (DSCSA) is not a huge shock. There has been widespread discussion surrounding how prepared the industry is to implement the appropriate measures to ensure compliance with the latest phase of the legislation.

In this Q&A with Securing Industry, Dexter Tjoa, director of corporate strategy talks about the impact of the enforcement delay on the industry and what the additional time means in practice for companies.

Read the full Q&A here: https://www.securingindustry.com/pharmaceuticals/dscsa-enforcement-delay-what-you-need-to-know/s40/a5226/#.WrUwLujFI2w